Pulmonx showed strong international performance and promising initiatives like direct-to-patient campaigns and AI screening tools. However, the need to revise revenue guidance due to slower U.S. growth and challenges in converting new commercial initiatives offset these achievements.

Company Guidance -

Q3 2025

During the Pulmonx Second Quarter 2025 Financial Results Conference Call, the company revised its full-year 2025 revenue guidance down to a range of $90 million to $92 million due to slower-than-expected growth in the U.S., particularly in procedure volume. Despite this, international revenue excelled, reaching $9.1 million, driven by robust growth in Europe and Asia. The company reported a 15% year-over-year increase in total worldwide revenue to $23.9 million, supported by sustained adoption of its Zephyr Valves. Gross margin for the quarter was 72%, slightly down from 74% a year prior. The company's efforts to expand capacity included opening 12 new screening centers and training 26 new physicians. It also noted record levels of StratX scans in June and July, signaling potential future growth. Pulmonx maintains a strong cash position, ending the quarter with $84.2 million in cash, cash equivalents, and marketable securities.

Strong International Revenue Growth

International revenue reached a record $9.1 million, a 32% increase from the previous year, highlighting strong global demand and commercial execution.

Increase in Total Worldwide Revenue

Total worldwide revenue for the second quarter was $23.9 million, marking a 15% year-over-year increase.

Expansion of Lung Cancer Screening

Lung cancer screening has tripled since 2020, generating millions of CT scans annually, creating opportunities for emphysema detection.

Direct-to-Patient Campaign Success

Direct-to-patient campaigns engaged over 70,000 first-time patients, contributing to one-third of the patients treated in 2025.

Launch of New AI Screening Tool

LungTraX Detect, an AI-powered screening tool, is being implemented in hospitals to identify emphysema patients from routine CT scans.

Pulmonx (LUNG) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

LUNG Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 29, 2025	2025 (Q3)	-0.42 / -	-0.36	―	―	―
Jul 30, 2025	2025 (Q2)	-0.39 / -0.38	-0.39	2.56% (+0.01)	―
Apr 30, 2025	2025 (Q1)	-0.40 / -0.36	-0.36	0.00% (0.00)	―
Feb 19, 2025	2024 (Q4)	-0.45 / -0.33	-0.36	8.33% (+0.03)	―
Oct 30, 2024	2024 (Q3)	-0.45 / -0.36	-0.39	7.69% (+0.03)	―
Jul 31, 2024	2024 (Q2)	-0.42 / -0.39	-0.43	9.30% (+0.04)	―
May 01, 2024	2024 (Q1)	-0.47 / -0.36	-0.42	14.29% (+0.06)	―
Feb 21, 2024	2023 (Q4)	-0.41 / -0.36	-0.38	5.26% (+0.02)	―
Oct 30, 2023	2023 (Q3)	-0.43 / -0.39	-0.38	-2.63% (-0.01)	―
Aug 02, 2023	2023 (Q2)	-0.44 / -0.43	-0.4	-7.50% (-0.03)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

LUNG Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 30, 2025	$3.15	$1.84	-41.59%
Apr 30, 2025	$4.83	$3.77	-21.95%
Feb 19, 2025	$6.64	$8.78	+32.23%
Oct 30, 2024	$6.79	$6.25	-7.95%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Pulmonx (LUNG) report earnings?

Pulmonx (LUNG) is schdueled to report earning on Oct 29, 2025, After Close (Confirmed).

What is Pulmonx (LUNG) earnings time?

Pulmonx (LUNG) earnings time is at Oct 29, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is LUNG EPS forecast?

LUNG EPS forecast for the fiscal quarter 2025 (Q3) is -0.42.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing